CSTF2 Supports Hypoxia Tolerance in Hepatocellular Carcinoma by Enabling m6A Modification Evasion of PGK1 to Enhance Glycolysis

被引:0
|
作者
Zhang, Qiangnu [1 ,2 ]
Zhang, Yusen [1 ]
Fu, Chuli [3 ]
He, Xiaoyan [4 ]
Huang, Zuotian [5 ,6 ]
Wu, Geyan [2 ]
Wei, Teng [7 ]
Jin, Wen [8 ]
Yan, Lesen [1 ]
Wu, Meilong [1 ]
Peng, Gongze [1 ]
Fan, Linlan [9 ]
Li, Mingyue [1 ]
Guo, Yuehua [1 ]
Bi, Jiangang [1 ]
Bai, Yu [1 ]
Roessler, Stephanie [10 ]
Yan, Guang-Rong [2 ]
Liu, Liping [1 ]
机构
[1] Southern Univ Sci & Technol, Jinan Univ, Affiliated Hosp 1, Shenzhen Peoples Hosp,Clin Med Coll 2,Dept Gen Sur, 17 Dongmen North Rd, Shenzhen 518020, Peoples R China
[2] Guangzhou Med Univ, Affiliated Hosp 3, Guangdong Prov Clin Res Ctr Obstet & Gynecol, Biomed Res Ctr,Guangdong Prov Key Lab Major Obstet, 63 Duobao Rd, Guangzhou 510150, Peoples R China
[3] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Dept Hematol & Oncol, Guangzhou, Peoples R China
[4] Zhengzhou Univ, Affiliated Hosp 5, Dept Pathol, Zhengzhou, Peoples R China
[5] Chongqing Univ, Canc Hosp, Dept Hepatobiliary, Chongqing, Peoples R China
[6] Chongqing Univ, Canc Hosp, Pancreat Tumor Ctr, Chongqing, Peoples R China
[7] Southern Univ Sci & Technol, Jinan Univ, Affiliated Hosp 1, Shenzhen Peoples Hosp,Clin Med Coll 2,Cytotherapy, Shenzhen, Peoples R China
[8] Southern Univ Sci & Technol, Jinan Univ, Shenzhen Peoples Hosp, Affiliated Hosp 1,Clin Med Coll 2,Dept Neurol, Shenzhen, Peoples R China
[9] Lanzhou Univ, Expt & teaching Ctr, Sch Basic Med Sci, Lanzhou, Peoples R China
[10] Heidelberg Univ Hosp, Inst Pathol, Heidelberg, Germany
基金
中国国家自然科学基金;
关键词
YTHDF PROTEINS; 3'UTR PROMOTES; MODEL;
D O I
10.1158/0008-5472.CAN-24-2283
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cleavage stimulation factor subunit 2 (CSTF2) is a fundamental factor in the regulation of 3 '-end cleavage and alternative polyadenylation of pre-mRNAs. Previous work has identified a tumor-promoting role of CSTF2, suggesting that it may represent a potential therapeutic target. In this study, we aimed to elucidate the mechanistic function of CSTF2 in hepatocellular carcinoma (HCC). CSTF2 upregulation was frequent in HCC, and elevated levels of CSTF2 correlated with poor patient prognosis. Although CSTF2 inhibition did not suppress HCC growth under nonstress conditions, it supported tolerance and survival of HCC cells under hypoxic conditions. Mechanistically, CSTF2 increased phosphoglycerate kinase 1 (PGK1) protein production to enhance glycolysis, thereby sustaining the energy supply under hypoxic conditions. CSTF2 shortened the 3 ' untranslated region of PGK1 pre-mRNA by binding near the proximal polyadenylation site. This shortening led to a loss of N6-methyladenosine (m6A) modification sites that are bound by YTH m6A RNA-binding protein F2 and increase degradation of PGK1 mRNA. Concurrently, hypoxia increased m6A modification of PGK1 mRNA near the proximal polyadenylation site that was recognized by the YTH m6A RNA-binding protein C1, which recruited CSTF2 to enhance the shortening of the PGK1 3 ' untranslated region. A small-molecule screen identified masitinib as an inhibitor of CSTF2. Masitinib counteracted PGK1 upregulation by CSTF2 and suppressed the growth of HCC xenograft and patient-derived organoid models. In conclusion, this study revealed a function of CSTF2 in supporting HCC survival under hypoxia conditions through m6A modification evasion and metabolic reprogramming, indicating that inhibiting CSTF2 may overcome hypoxia tolerance in HCC.Significance: Targeting CSTF2 inhibits hepatocellular carcinoma survival in hypoxic microenvironments, which may be a promising therapeutic strategy for treating liver cancer.
引用
收藏
页码:515 / 534
页数:20
相关论文
共 50 条
  • [41] LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2
    Wang, Fan
    Hu, Yuhang
    Wang, Hongda
    Hu, Ping
    Xiong, Hewei
    Zeng, Zhu
    Han, Shengbo
    Wang, Decai
    Wang, Jie
    Zhao, Yong
    Huang, Yan
    Zhuo, Wenfeng
    Lv, Guozheng
    Zhao, Gang
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2023, 42 (01)
  • [42] LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2
    Fan Wang
    Yuhang Hu
    Hongda Wang
    Ping Hu
    Hewei Xiong
    Zhu Zeng
    Shengbo Han
    Decai Wang
    Jie Wang
    Yong Zhao
    Yan Huang
    Wenfeng Zhuo
    Guozheng Lv
    Gang Zhao
    Journal of Experimental & Clinical Cancer Research, 42
  • [43] METTL3-mediated m6A modification of lncRNA TSPAN12 promotes metastasis of hepatocellular carcinoma through SENP1-depentent deSUMOylation of EIF3I
    Bei Li
    Xianze Xiong
    Jianrong Xu
    Dingzhong Peng
    Guilin Nie
    Ningyuan Wen
    Yaoqun Wang
    Jiong Lu
    Oncogene, 2024, 43 : 1050 - 1062
  • [44] METTL3-mediated m6A modification of lncRNA TSPAN12 promotes metastasis of hepatocellular carcinoma through SENP1-depentent deSUMOylation of EIF3I
    Li, Bei
    Xiong, Xianze
    Xu, Jianrong
    Peng, Dingzhong
    Nie, Guilin
    Wen, Ningyuan
    Wang, Yaoqun
    Lu, Jiong
    ONCOGENE, 2024, 43 (14) : 1063 - 1074
  • [45] Down-regulated FTO and ALKBH5 co-operatively activates FOXO signaling through m6A methylation modification in HK2 mRNA mediated by IGF2BP2 to enhance glycolysis in colorectal cancer
    Mujie Ye
    Jinhao Chen
    Feiyu Lu
    Minghui Zhao
    Suwen Wu
    Chunhua Hu
    Ping Yu
    Jingbao Kan
    Jianan Bai
    Ye Tian
    Qiyun Tang
    Cell & Bioscience, 13
  • [46] Down-regulated FTO and ALKBH5 co-operatively activates FOXO signaling through m6A methylation modification in HK2 mRNA mediated by IGF2BP2 to enhance glycolysis in colorectal cancer
    Ye, Mujie
    Chen, Jinhao
    Lu, Feiyu
    Zhao, Minghui
    Wu, Suwen
    Hu, Chunhua
    Yu, Ping
    Kan, Jingbao
    Bai, Jianan
    Tian, Ye
    Tang, Qiyun
    CELL AND BIOSCIENCE, 2023, 13 (01):
  • [47] METTL16/IGF2BP2 axis enhances malignant progression and DDP resistance through up-regulating COL4A1 by mediating the m6A methylation modification of LAMA4 in hepatocellular carcinoma
    Liming Cao
    Wei Bi
    Cell Division, 20 (1)
  • [48] Long noncoding RNA lnc-H2AFV-1 promotes cell growth by regulating aberrant m6A RNA modification in head and neck squamous cell carcinoma
    Chen, Xi
    Liu, Yunxia
    Sun, Dongyuan
    Sun, Rongqi
    Wang, Xiaoxiao
    Li, Minmin
    Song, Ning
    Ying, Jicheng
    Guo, Tao
    Jiang, Yingying
    CANCER SCIENCE, 2022, 113 (06) : 2071 - 2084
  • [49] m6A Modification-Mediated DUXAP8 Regulation of Malignant Phenotype and Chemotherapy Resistance of Hepatocellular Carcinoma Through miR-584-5p/MAPK1/ERK Pathway Axis
    Liu, Zefeng
    Lu, Jin
    Fang, He
    Sheng, Jiyao
    Cui, Mengying
    Yang, Yongsheng
    Tang, Bo
    Zhang, Xuewen
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [50] METTL14-mediated Lnc-LSG1 m6A modification inhibits clear cell renal cell carcinoma metastasis via regulating ESRP2 ubiquitination
    Shen, Danyang
    Ding, Lifeng
    Lu, Zeyi
    Wang, Ruyue
    Yu, Chenhao
    Wang, Huan
    Zheng, Qiming
    Wang, Xuliang
    Xu, Wanjiang
    Yu, Haifeng
    Xu, Liwei
    Wang, Mingchao
    Yu, Shicheng
    Zhu, Shibin
    Qian, Jun
    Xia, Liqun
    Li, Gonghui
    MOLECULAR THERAPY NUCLEIC ACIDS, 2022, 27 : 547 - 561